

**Amendments to the Claims**

Please cancel claims 48 and 49. This listing of claims will replace all prior versions and listings of claims in this application:

**Listing of Claims:**

**Claims 1-6 (Canceled)**

7. (Previously presented) The monoclonal antibody of claim 33, wherein the antibody is a scFv.

8. (Previously presented) The monoclonal antibody of claim 33, wherein the antibody is a Fab.

9. (Previously presented) The monoclonal antibody of claim 33, wherein the antibody is a fully assembled antibody.

**Claims 10-12 (Canceled)**

13. (Withdrawn) A monoclonal antibody that specifically binds to a human VEGF and has  $V_L$  comprising the amino acid sequence of

$X_1X_2X_3X_4TQX_5PSX_6X_7SX_8X_9X_{10}GX_{11}X_{12}X_{13}X_{14}IX_{15}CX_{16}X_{17}SX_{18}X_{19}IX_{20}X_{21}X_2$   
 $_2X_{23}X_{24}WYQQX_{25}PGX_{26}APX_{27}X_{28}LX_{29}YX_{30}X_{31}X_{32}X_{33}LX_{34}X_{35}GVX_{36}X_{37}RFSGX_{38}X_{39}SGT$   
 $DFX_{40}LTIX_{41}X_{42}LQX_{43}X_{44}DX_{45}AX_{46}YYCQQX_{47}X_{48}X_{49}X_{50}PX_{51}TFGX_{52}GTKX_{53}X_{54}IK$ ,  
wherein the underlined regions are designated as  $V_L/CDR1$ ,  $V_L/CDR2$ , and  $V_L/CDR3$ , respectively, whereas the rest of the region is designated as framework, and wherein  $X_1$  is D, E or A;  $X_2$  is I, or T;  $X_3$  is V, E, K, R, Q, or T;  $X_4$  is M, or L;  $X_5$  is S, or T,  $X_6$  is S, or T;  $X_7$  is L, or V;  $X_8$  is A, or V;  $X_9$  is S, or T;  $X_{10}$  is P, V, L, A, or I;  $X_{11}$  is E, or D;  $X_{12}$  is R, or T;  $X_{13}$  is A, or V I;  $X_{14}$  is T, or A;  $X_{15}$  is T, S, or A;  $X_{16}$  is S, R, N, K, H, or Q;  $X_{17}$  is A, or S;  $X_{18}$  is Q, or R;  $X_{19}$  is S, D, A, or P;  $X_{20}$  is S, G, R, T, or Y;  $X_{21}$  is T, N, S, D, or K;  $X_{22}$  is Y, or D;  $X_{23}$  is L, or I;  $X_{24}$  is A, N, or T;  $X_{25}$  is K, or I;  $X_{26}$  is Q, K, T, or I;  $X_{27}$  is R, K, Q, N, H, S, or E;  $X_{28}$  is V, or L;  $X_{29}$  is I, or V;  $X_{30}$  is F, A, G, D, or S;  $X_{31}$  is A, or T;  $X_{32}$  is S, or T;  $X_{33}$  is N, S, R, or T;  $X_{34}$  is A, H, or Q;  $X_{35}$  is S, or G;  $X_{36}$  is P, T;  $X_{37}$  is S, N, D, G, or Y;  $X_{38}$  is S, or T;  $X_{39}$  is G, or R;  $X_{40}$  is T, or A;  $X_{41}$  is S, or R;  $X_{42}$  is S, or R;  $X_{43}$  is P, or A;  $X_{44}$

is E , or D; X<sub>45</sub> is F, V, or S; X<sub>46</sub> is V, T, I , A , or S; X<sub>47</sub> is Y, or S; X<sub>48</sub> is S, Y, or N; X<sub>49</sub> is S, or T; X<sub>50</sub> is T, V, A, P, K, G, S, or I; X<sub>51</sub> is W , or Y; X<sub>52</sub> is Q , or G; X<sub>53</sub> is V, or L; and X<sub>54</sub> is E, D , or A.

14. (Withdrawn) A monoclonal antibody that specifically binds to a human VEGF and has V<sub>L</sub> comprising the amino acid sequence of

X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>LTQPPSX<sub>4</sub>SX<sub>5</sub>TPGQX<sub>6</sub>VTISCSGX<sub>7</sub>X<sub>8</sub>SNX<sub>9</sub>GX<sub>10</sub>NX<sub>11</sub>VX<sub>12</sub>WYQQX<sub>13</sub>P  
GX<sub>14</sub>APKX<sub>15</sub>LX<sub>16</sub>YX<sub>17</sub>NX<sub>18</sub>X<sub>19</sub>RPSGV<sub>20</sub>RX<sub>21</sub>SGSX<sub>22</sub>SX<sub>23</sub>TSASLAISGLX<sub>24</sub>SEDEADY  
YC<sub>25</sub>X<sub>26</sub>WDDSLX<sub>27</sub>GYVFGX<sub>28</sub>GTX<sub>29</sub>LT<sub>29</sub>TVL, wherein the underlined regions are designated as V<sub>L</sub>/CDR1, V<sub>L</sub>/CDR2, and V<sub>L</sub>/CDR3, respectively, whereas the rest of the region is designated as framework, and wherein X<sub>1</sub> is Q L, or N; X<sub>2</sub> is P A F, or S; X<sub>3</sub> is V, or M; X<sub>4</sub> is A, or T; X<sub>5</sub> is G, or A; X<sub>6</sub> is R, or S; X<sub>7</sub> is S, or T; X<sub>8</sub> is S, T Y, or N; X<sub>9</sub> is I , or V; X<sub>10</sub> is S, or R; X<sub>11</sub> is S, P, N, A, or T; X<sub>12</sub> is N, T , or Y; X<sub>13</sub> is L, or F; X<sub>14</sub> is T, or A; X<sub>15</sub> is V, L, or F; X<sub>16</sub> is M, or I; X<sub>17</sub> is G, T, or S; X<sub>18</sub> is N, or D; X<sub>19</sub> is Q, or E; X<sub>20</sub> is D, or E; X<sub>21</sub> is F, or L; X<sub>22</sub> is K, or R; X<sub>23</sub> is G, or A; X<sub>24</sub> is Q, L, or R; X<sub>25</sub> is A, or G; X<sub>26</sub> is A, S, or T; X<sub>27</sub> is N, S, or T; X<sub>28</sub> is T, or A; and X<sub>29</sub> is K, or Q.

15. (Withdrawn) A monoclonal antibody that specifically binds to a human VEGF and has V<sub>L</sub> comprising the amino acid sequence of

QSALTQPPSVSGAPGQRVTISCTGRSSNIGAGHDVHWYQQLPGTAPKLLIY  
ANDQRPSGV<sub>20</sub>PDRFSDSKSGTSASLGISGLRSEDEADYFCATWDDSLHGYVFGTGTKV  
TVL (SEQ ID No: 54).

16. (Withdrawn) A monoclonal antibody is provided that specifically binds to a human VEGF and has V<sub>H</sub> comprising the amino acid sequence of

X<sub>1</sub>X<sub>2</sub>QLVX<sub>3</sub>SGGGX<sub>4</sub>VQPGGX<sub>5</sub>LRLX<sub>6</sub>CAX<sub>7</sub>SGX<sub>8</sub>X<sub>9</sub>X<sub>10</sub>X<sub>11</sub>X<sub>12</sub>X<sub>13</sub>GX<sub>14</sub>NWX<sub>15</sub>  
RQAPGKGX<sub>16</sub>EWVGWX<sub>17</sub>NTX<sub>18</sub>X<sub>19</sub>GX<sub>20</sub>X<sub>21</sub>TYX<sub>22</sub>X<sub>23</sub>X<sub>24</sub>FX<sub>25</sub>RRX<sub>26</sub>TX<sub>27</sub>SX<sub>28</sub>X<sub>29</sub>X<sub>30</sub>SK  
X<sub>31</sub>X<sub>32</sub>X<sub>33</sub>YLQX<sub>34</sub>NSLRAEDTAVYYCAX<sub>35</sub>YPX<sub>36</sub>YYGX<sub>37</sub>SHWYFDVWX<sub>38</sub>QGTLVTVS  
S, wherein the underlined regions are designated as CDR1, CDR2, and CDR3, respectively, whereas the rest of the region is designated as framework according to Kabat nomenclature, and wherein X<sub>1</sub> is E, or Q; X<sub>2</sub> is V, or G; X<sub>3</sub> is Q, or E; X<sub>4</sub> is V, or L; X<sub>5</sub> is S, or T; X<sub>6</sub> is S T, or R; X<sub>7</sub> is A, or V; X<sub>8</sub> is Y, or F; X<sub>9</sub> is T, D, N, S, or A; X<sub>10</sub> is F, or L; X<sub>11</sub> is T, D, Y, A, S, or N; X<sub>12</sub> is N, H, or S; X<sub>13</sub> is Y, or F; X<sub>14</sub> is M, L, I, or V; X<sub>15</sub> is I, V, or L; X<sub>16</sub> is L, or P;

X<sub>17</sub> is I, or V; X<sub>18</sub> is Y, or N; X<sub>19</sub> is T, or N; X<sub>20</sub> is E, or A; X<sub>21</sub> is P, T, or S; X<sub>22</sub> is A, or V; X<sub>23</sub> is A, H, Q, P, D, or E; X<sub>24</sub> is D, or E; X<sub>25</sub> is K, or T; X<sub>26</sub> is V, F, or L; X<sub>27</sub> is F, or I; X<sub>28</sub> is L, or R; X<sub>29</sub> is D, or N; X<sub>30</sub> is T, or N; X<sub>31</sub> is S, or N; X<sub>32</sub> is T, Q, P, or K; X<sub>33</sub> is A, V, or P; X<sub>34</sub> is L, or M; X<sub>35</sub> is K, or R; X<sub>36</sub> is H, or Y; X<sub>37</sub> is S, R, or T; and X<sub>38</sub> is G, or A.

17. (Withdrawn) A monoclonal antibody is provided that specifically binds to a human VEGF and has V<sub>L</sub> comprising the amino acid sequence selected from the group consisting of SEQ ID NOs:2-54, more preferably comprising the amino acid sequence selected from the group consisting of SEQ ID NO:14, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:44, SEQ ID NO:47, and SEQ ID NO:54.

18. (Withdrawn) A monoclonal antibody that specifically binds to a human VEGF and has V<sub>H</sub> comprising the amino acid sequence selected from the group consisting of SEQ ID NOs:57-110 and SEQ ID NOs:285-310, and preferably comprising the amino acid sequence selected from the group consisting of SEQ ID NOs:61-64, SEQ ID NOs:67, 68, 70, 75, 83, 88, 89, 90, 91, 92, 93, 94, and 96-110.

19. (Withdrawn) A monoclonal antibody is provided that specifically binds to a human VEGF and has CDR2 in the V<sub>L</sub> region (V<sub>L</sub>/CDR2) comprising the amino acid sequence selected from the group consisting of SEQ ID NOs:195-209.

20. (Withdrawn) A monoclonal antibody that specifically binds to a human VEGF and has CDR3 in the V<sub>L</sub> region (V<sub>L</sub>/CDR3) comprising the amino acid sequence selected from the group consisting of SEQ ID NOs:210-228.

21. (Withdrawn) A monoclonal antibody that specifically binds to a human VEGF and has a framework region (FR) CDR3 in the V<sub>L</sub> region (V<sub>L</sub>/FR) comprising the amino acid sequence selected from the group consisting of: SEQ ID NO:229-269, and preferably comprising the amino acid sequence selected from the group consisting of SEQ ID NO:232, 235, 237, 251, 255, 263, and 265.

22. (Withdrawn) A monoclonal antibody that specifically binds to a human VEGF and has CDR1 in the V<sub>H</sub> region (V<sub>H</sub>/CDR1) comprising the amino acid sequence of

$\text{GX}_1\text{X}_2\text{X}_3\text{X}_4\text{X}_5\text{X}_6\text{GX}_7\text{N}$ , wherein  $\text{X}_1$  is Y, or F;  $\text{X}_2$  is D, N, T, S, or A;  $\text{X}_3$  is F, or L;  $\text{X}_4$  is T, D, S, Y, A, or N;  $\text{X}_5$  is H, N, or S;  $\text{X}_6$  is Y, or F;  $\text{X}_7$  is M, L, I, or V.

23. (Withdrawn) A monoclonal antibody that specifically binds to a human VEGF and has CDR2 in the  $\text{V}_\text{H}$  region ( $\text{V}_\text{H}$  /CDR2) comprising the amino acid sequence of  $\text{WX}_1\text{NTX}_2\text{X}_3\text{GEX}_4\text{TYX}_5\text{X}_6\text{X}_7\text{FX}_8\text{R}$ , wherein  $\text{X}_1$  is I, or V;  $\text{X}_2$  is Y, or N;  $\text{X}_3$  is T, or N;  $\text{X}_4$  is P, T, or S;  $\text{X}_5$  is A, or V;  $\text{X}_6$  is A, Q, P, H, D, or E;  $\text{X}_7$  is D, or E; and  $\text{X}_8$  is K, or T.

24. (Withdrawn) A monoclonal antibody that specifically binds to a human VEGF and has CDR2 in the  $\text{V}_\text{H}$  region ( $\text{V}_\text{H}$  /CDR2) comprising the amino acid sequence selected from the group consisting of: SEQ ID NOs:136-156.

25. (Withdrawn) A monoclonal antibody that specifically binds to a human VEGF and has CDR3 in the  $\text{V}_\text{H}$  region ( $\text{V}_\text{H}$  /CDR3) comprising the amino acid sequence of  $\text{KYPX}_1\text{YYGX}_2\text{SHWYFDV}$ , wherein  $\text{X}_1$  is Y, or H, and  $\text{X}_2$  is R.

26. (Withdrawn) A monoclonal antibody that specifically binds to a human VEGF and has CDR3 in the  $\text{V}_\text{H}$  region ( $\text{V}_\text{H}$  /CDR3) comprising the amino acid sequence selected from the group consisting of SEQ ID NOs:311-337.

27. (Withdrawn) A monoclonal antibody that specifically binds to a human VEGF and has FR in the  $\text{V}_\text{H}$  region ( $\text{V}_\text{H}$  /FR) comprising the amino acid sequence of  $\text{X}_1\text{VQLVX}_2\text{SGGGX}_3\text{VQPGGX}_4\text{LRLX}_5\text{CAX}_6\text{S}/\text{CDR1/WX}_7\text{RQAPGKGLEWVG/CDR2/RX}_8\text{TX}_9\text{SX}_10\text{DX}_11\text{SKX}_12\text{X}_13\text{X}_14\text{YLQX}_15\text{NSLRAEDTAVYYCA/CDR3/WX}_16\text{QGTLVTVSS}$ , wherein  $\text{X}_1$  is E, or Q;  $\text{X}_2$  is Q, or E;  $\text{X}_3$  is V, or L;  $\text{X}_4$  is S, or T;  $\text{X}_5$  is S, T, or R;  $\text{X}_6$  is A, or V;  $\text{X}_7$  is I, or V;  $\text{X}_8$  is F, or V;  $\text{X}_9$  is F, or I;  $\text{X}_{10}$  is L, or R is  $\text{X}_{11}$  is T, or N;  $\text{X}_{12}$  is S, or N;  $\text{X}_{13}$  is T, Q, or K;  $\text{X}_{14}$  is A, or V;  $\text{X}_{15}$  is M, or L; and  $\text{X}_{16}$  is G, or A.

28. (Previously Presented) A monoclonal antibody that specifically binds to a human VEGF and has a  $\text{V}_\text{L}$  and  $\text{V}_\text{H}$  pair selected from the group consisting of: SEQ ID NO:28 and 88; SEQ ID NO:28 and 90; SEQ ID NO:28 and 91; SEQ ID NO:28 and 106; SEQ ID NO:28 and 107; SEQ ID NO:28 and 108; and SEQ ID NO:28 and 109.

29. (Withdrawn) The monoclonal antibody of any of claims 14-29, wherein the antibody has dissociation constant  $K_d$  equal to or lower than 10 nM.

30. (Withdrawn) The monoclonal antibody of any of claims 14-29, wherein the antibody has dissociation constant  $K_d$  equal to or lower than 1 nM.

31. (Withdrawn) The monoclonal antibody of any of claims 14-29, wherein the antibody has dissociation constant  $K_d$  equal to or lower than 0.1 nM.

32. (Withdrawn) The monoclonal antibody of any of claims 14-29, wherein the antibody has dissociation constant  $K_d$  equal to or lower than 0.01 nM.

33. (Previously presented) A monoclonal antibody that specifically binds to human VEGF and has a VL and VH pair selected from the group consisting of: SEQ ID NO:26 and 88; SEQ ID NOs:26 and 90; SEQ ID NOs:26 and 91; SEQ ID NOs:26 and 106; SEQ ID NOs:26 and 107; SEQ ID NOs:26 and 108; SEQ ID NOs:26 and 109; SEQ ID NOs:28 and 88; SEQ ID NOs:28 and 90; SEQ ID NOs:28 and 91; SEQ ID NOs:28 and 106; SEQ ID NOs:28 and 107; SEQ ID NOs:28 and 108; SEQ ID NOs:28 and 109; SEQ ID NOs:36 and 88; SEQ ID NOs:36 and 90; SEQ ID NOs:36 and 91; SEQ ID NOs:36 and 106; SEQ ID NOs:36 and 107; SEQ ID NOs:36 and 108; and SEQ ID NOs:36 and 109.

34. (Previously presented) A monoclonal antibody that specifically binds to human VEGF and has a VL and VH pair selected from the group consisting of: SEQ ID NOs:26 and 106; SEQ ID NOs:28 and 106; and SEQ ID NOs:36 and 106.

35. (Previously presented) A monoclonal antibody that specifically binds to human VEGF and has a  $V_L$  and  $V_H$  pair consisting of SEQ ID NOs:28 and 106.

36. (Previously presented) A monoclonal antibody that specifically binds to human VEGF and has a VL domain consisting of SEQ ID NO:28 in combination with a VH domain selected from SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:88, SEQ ID NO:90, and SEQ ID NO:91 .

37. (Previously presented) The monoclonal antibody of claim 35, wherein the antibody is a scFv.

38. (Previously presented) The monoclonal antibody of claim 35, wherein the antibody is a Fab.

39. (Previously presented) The monoclonal antibody of claim 35, wherein the antibody is a fully assembled antibody.

40. (Withdrawn) A recombinant antibody that specifically binds to a human VEGF and has a light chain variable domain ( $V_L$ ) comprising CDR1, CDR2 and CDR3 regions consisting of the amino acid sequences set forth in SEQ ID NO:172, SEQ ID NO:195 and SEQ ID NO:212, respectively.

41. (Withdrawn) The recombinant antibody according to claim 40, wherein the heavy chain variable domain ( $V_H$ ) comprises CDR1, CDR2, and CDR3 regions consisting of the amino acid sequences set forth in SEQ ID NO:31, SEQ ID NO:152 and SEQ ID NO:327, respectively.

42. (Withdrawn) The recombinant antibody of claim 41, wherein the antibody is a scFv.

43. (Withdrawn) The recombinant antibody of claim 41, wherein the antibody is a Fab.

44. (Withdrawn) The recombinant antibody of claim 41, wherein the antibody is a fully assembled antibody.

45. (Withdrawn) A recombinant antibody that specifically binds to human VEGF and has a  $V_L$  domain comprising CDR1, CDR2 and CDR3 regions consisting of the amino acid sequences set forth in SEQ ID NO:170, SEQ ID NO:195 and SEQ ID NO:214, respectively.

46. (Withdrawn) A recombinant antibody that specifically binds to human VEGF and has a V<sub>H</sub> domain comprising CDR1, CDR2, and CDR3 regions consisting of the amino acid sequences set forth in SEQ ID NO:31, SEQ ID NO:152 and SEQ ID NO:327, respectively.

47. (Withdrawn) A recombinant antibody that specifically binds to human VEGF and has V<sub>L</sub> comprising CDR1, CDR2 and CDR3 regions consisting of the amino acid sequences set forth in SEQ ID NO:182, SEQ ID NO:201 and SEQ ID NO:222, respectively.

48. (Canceled)

49. (Canceled)